These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37142094)

  • 21. The importance of heteroresistance and efflux pumps in bedaquiline-resistant Mycobacterium tuberculosis isolates from Iran.
    Madadi-Goli N; Ahmadi K; Kamakoli MK; Azizi M; Khanipour S; Dizaji SP; Nasehi M; Siadat SD; Fateh A; Vaziri F
    Ann Clin Microbiol Antimicrob; 2024 Apr; 23(1):36. PubMed ID: 38664815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis isolates circulating in Shaanxi, China.
    Yang J; Pang Y; Zhang T; Xian X; Li Y; Wang R; Wang P; Zhang M; Wang J
    Int J Infect Dis; 2020 Oct; 99():163-170. PubMed ID: 32738481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan.
    Wu SH; Chan HH; Hsiao HC; Jou R
    Front Microbiol; 2021; 12():754249. PubMed ID: 34745058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis.
    Maartens G; Brill MJE; Pandie M; Svensson EM
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):26-29. PubMed ID: 29145924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis.
    Pang Y; Jing W; Lu J; Zong Z; Huo F; Dong L; Dai G; Li Y; Huang H; Chu N
    Diagn Microbiol Infect Dis; 2019 Aug; 94(4):361-364. PubMed ID: 30876684
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Zhang L; Zhang Y; Li Y; Huo F; Chen X; Zhu H; Guo S; Fu L; Wang B; Lu Y
    Microbiol Spectr; 2023 Aug; 11(5):e0000223. PubMed ID: 37615440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant
    Almeida D; Converse PJ; Li SY; Upton AM; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0141221. PubMed ID: 34570644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey.
    Wang G; Jiang G; Jing W; Zong Z; Yu X; Chen S; Li W; Huang H
    J Infect; 2021 Mar; 82(3):371-377. PubMed ID: 33556430
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Degiacomi G; Sammartino JC; Sinigiani V; Marra P; Urbani A; Pasca MR
    Front Microbiol; 2020; 11():559469. PubMed ID: 33042066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants.
    Ismail N; Omar SV; Ismail NA; Peters RPH
    J Microbiol Methods; 2018 Oct; 153():1-9. PubMed ID: 30165087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The TetR Family Transcription Factor MAB_2299c Regulates the Expression of Two Distinct MmpS-MmpL Efflux Pumps Involved in Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus.
    Gutiérrez AV; Richard M; Roquet-Banères F; Viljoen A; Kremer L
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332077
    [No Abstract]   [Full Text] [Related]  

  • 32. Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China.
    Zheng H; He W; Jiao W; Xia H; Sun L; Wang S; Xiao J; Ou X; Zhao Y; Shen A
    BMC Infect Dis; 2021 Apr; 21(1):330. PubMed ID: 33832459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
    Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G
    Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced susceptibility and resistance to bedaquiline in clinical M. tuberculosis isolates.
    Peretokina IV; Krylova LY; Antonova OV; Kholina MS; Kulagina EV; Nosova EY; Safonova SG; Borisov SE; Zimenkov DV
    J Infect; 2020 May; 80(5):527-535. PubMed ID: 31981638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era.
    Beckert P; Sanchez-Padilla E; Merker M; Dreyer V; Kohl TA; Utpatel C; Köser CU; Barilar I; Ismail N; Omar SV; Klopper M; Warren RM; Hoffmann H; Maphalala G; Ardizzoni E; de Jong BC; Kerschberger B; Schramm B; Andres S; Kranzer K; Maurer FP; Bonnet M; Niemann S
    Genome Med; 2020 Nov; 12(1):104. PubMed ID: 33239092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant
    Xu J; Converse PJ; Upton AM; Mdluli K; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis.
    Almeida D; Ioerger T; Tyagi S; Li SY; Mdluli K; Andries K; Grosset J; Sacchettini J; Nuermberger E
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4590-9. PubMed ID: 27185800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China.
    Liu Y; Gao M; Du J; Wang L; Gao J; Shu W; Wang Y; Xue Z; Li L; Pang Y
    Clin Infect Dis; 2021 Nov; 73(9):e3391-e3397. PubMed ID: 32667984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
    Kim S; Louie A; Drusano GL; Almoslem M; Kim S; Myrick J; Nole J; Duncanson B; Peloquin CA; Scanga CA; Yamada W; Neely M; Schmidt S
    Int J Antimicrob Agents; 2022 Feb; 59(2):106509. PubMed ID: 34958863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutation in
    Singh BK; Soneja M; Sharma R; Chaubey J; Kodan P; Jorwal P; Nischal N; Chandra S; Ramachandran R; Wig N
    Int J Mycobacteriol; 2020; 9(2):212-215. PubMed ID: 32474547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.